Home About Us Solutions Technology Events Contact Us
Innovation Vision Awards

Relentless Innovation: How Passion and Perseverance Can Lead to Cutting-Edge Technology

David Ecker, Ph.D., Divisional Vice President, Abbott Ibis Biosciences, Research and Development

Watch Now

 

The Challenge

There is an urgent need for a diagnostic tool to bridge the gap between treating rapidly and treating optimally

Rapid and Comprehensive Detection

“…early recognition of life-threatening infection and rapid initiation of appropriate antimicrobial therapy is the critical element in reducing mortality. The challenge that hospitals now face is how best to implement systems to facilitate this goal.”

Funk DJ, Kumar A. Antimicrobial Therapy for Life Threatening Infections: Speed is Life. Critical Care Clinics. 2011;
27:53-76.



The Solution

Expanding the frontiers of molecular diagnostics

IRIDICA Logo

IRIDICA sets completely new expectations for comprehensive results and turnaround times. By testing directly from clinical specimens, IRIDICA is at the forefront of the evolution of microbial diagnostics. In approximately 6 hours, your laboratory can provide the insights that may lead to optimal antimicrobial therapy, sooner.

CE Marked. For In Vitro Diagnostic Use. Not commercially available in the United States.

Transforming Patient Care with a Breakthrough Solution

About Abbott Ibis Biosciences

The mission of Ibis Biosciences is to create diagnostic solutions that can provide faster, actionable results for critical infections. Ibis Biosciences is focused on delivering an innovative approach to the detection and characterization of a broad array of microorganisms, contributing to Abbott’s expanding role in molecular testing.

Learn more about Ibis innovation

CE Marked. For In Vitro Diagnostic Use. Not commercially available in the United States.

 

Scientific Achievements and Recognition

  • The technology was recognized for its potential in infection control and bio‐threat agent identification. As a result, initial research was funded by Defense Advanced Research Projects Agency (DARPA), Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), Federal Bureau of Investigation (FBI) and Department of Human Services (DHS), among others.
  • In spring 2009, the technology helped the Naval Health Research Center in San Diego identify the first cases of a new variant of influenza virus outbreak in the U.S.
  • In 2009, the technology received the ‘Overall Gold Award,’ the highest recognition at the Wall Street Journal Technology Innovation Awards.
  • The technology has been used in multiple scientific research studies resulting in approximately 100 peer‐reviewed, scientific publications.



As molecular diagnostics providers, our business includes instruments and reagents used to analyze DNA and RNA. For more information, visit the Abbott Molecular website.